Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.

Scosyrev E, Wu G, Mohile S, Messing EM.

Cancer. 2012 Dec 1;118(23):5768-76. doi: 10.1002/cncr.27503. Epub 2012 Jul 30.

2.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
3.

Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.

Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.

PMID:
25556937
4.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
5.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
6.

Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

Welch HG, Fisher ES, Gottlieb DJ, Barry MJ.

J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. Epub 2007 Sep 11.

PMID:
17848671
7.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS.

Cancer Causes Control. 1998 Oct;9(5):519-27.

PMID:
9934717
8.

Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.

Schwartz KL, Severson RK, Gurney JG, Montie JE.

Cancer. 1996 Sep 15;78(6):1260-6.

9.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

10.

Trends in prostate cancer mortality among black men and white men in the United States.

Chu KC, Tarone RE, Freeman HP.

Cancer. 2003 Mar 15;97(6):1507-16.

11.

Towards an optimal interval for prostate cancer screening.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.

Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.

PMID:
21840117
12.

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.

Etzioni R, Berry KM, Legler JM, Shaw P.

Urology. 2002 Feb;59(2):251-5.

PMID:
11834397
13.

PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.

Wachtel MS, Nelius T, Haynes AL, Dahlbeck S, de Riese W.

Prostate. 2013 Sep;73(12):1365-9. doi: 10.1002/pros.22680. Epub 2013 May 6.

PMID:
23649537
14.
15.

PSA-use in a Spanish industrial area.

Páez A, Luján M, Llanes L, Romero I, de la Cal MA, Miravalles E, Berenguer A.

Eur Urol. 2002 Feb;41(2):162-6.

PMID:
12074403
16.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS.

J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24.

PMID:
10379964
17.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.

PMID:
16077071
18.

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM.

JAMA. 2015 Nov 17;314(19):2054-61. doi: 10.1001/jama.2015.14905.

PMID:
26575061
19.
20.

Supplemental Content

Support Center